Topical TolaSure cream for epidermolysis bullosa simplex
Part of Genetic & congenital, Skin clinical trials.
This study tests a medicated cream called TolaSure on skin affected by epidermolysis bullosa simplex (EBS), a condition that causes fragile skin and blistering. The cream aims to reduce blistering and improve healing by targeting a faulty protein in the skin. It is for people with localized, intermediate, or severe EBS who are currently having active blistering.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 2 years or older
- Diagnosis of localized, intermediate, or severe epidermolysis bullosa simplex (EBS) with a confirmed gene change in KRT5 or KRT14
- For localized EBS: blistering covering at least 15% of the bottom of one foot
- For intermediate or severe EBS: an active flare with blisters covering at least 2-3% of your body
- No infected skin areas or use of topical antibiotics on target skin within 14 days
- Able to avoid other topical creams or medicated dressings on the treated areas during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a gel called Filsuvez helps heal blisters and sores in people with epidermolysis bullosa simplex (EBS). It might reduce pain and improve skin healing.
This study tests whether a daily pill called apremilast can reduce the number of new blisters in people with a genetic form of EBS (epidermolysis bullosa simplex). If you get more than 3 new blisters per day and have a confirmed KRT5 or KRT14 mutation, this trial may be a good fit.
This study tests a medication called deucravacitinib for adults with rare genetic skin conditions that cause blisters or severe scaling. The goal is to see if it can reduce symptoms safely.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
Hear when a new Epidermolysis Bullosa Simplex trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.